Stem Cell Lines and Paid-for Eggs: Stem Cell Agency Delays Action on Easing Restrictions
By David Jensen,
California Stem Cell Report
| 07. 24. 2013
A key panel of the California stem cell agency today balked at approving a plan to ease restrictions on using stem cell lines derived from women who were paid for their eggs.
The proposal had been scheduled to be taken up tomorrow by the governing board of the $3 billion agency, but
the board's standards working group delayed action.
In response to a question, Kevin McCormack, a spokesman for the agency, said in an email,
“It was felt that more discussion was needed before moving to a vote so another meeting is going to be scheduled.”
In 2006, the CIRM governing board approved regulations that banned the use of CIRM funds for stem cells lines derived using compensation. That rule would be modified under today's plan, which would permit the CIRM governing board to approve the use of such lines following a staff study evaluating scientific and ethical issues. Their use would be allowed if the lines would “advance CIRM's mission.”
The delay came after four organizations, including the Center for Genetics and Society in Berkeley, argued that the plan...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
By Ryan Knutson and Jessica Mendoza, The Journal. | 03.27.2026
Genetically engineered babies are banned in the U.S. But that isn’t stopping Silicon Valley tech titans from trying to make one. In this final installment from The Journal’s investigation into the fringes of the fertility industry, WSJ’s Emily Glazer reports...
By Antonio Regalado, MIT Technology Review | 03.30.2026
After operating in secrecy for years, a startup company called R3 Bio, in Richmond, California, suddenly shared details about its work last week—saying it had raised money to create nonsentient monkey “organ sacks” as an alternative to animal testing.
In...